However, the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus (MILES) trial revealed that sirolimus, a mechanistic target of rapamycin inhibitor, stabilizes lung function, reduces serum vascular endothelial growth factor-D (VEGF-D) levels, and ameliorates symptoms2. This evidence concerns the gene VEGFD and lymphangioleiomyomatosis.